Patents by Inventor Heoun Jeong GO

Heoun Jeong GO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200396973
    Abstract: Provided are a psoriasis-induced transgenic animal model overexpressing the Pellino homolog 1 (Peli1) gene according to doxycycline administration, and a use thereof. The transgenic animal model of the present disclosure exhibited similarity to phenotypes shown in patients with psoriasis, due to overexpression of the Pellino homolog 1 (Peli1) gene according to doxycycline administration. It is anticipated that the transgenic animal model may be usefully used in clinical studies, such as screening for a candidate drug for the treatment of psoriasis. Additionally, it is anticipated that a peptide derived from the Peli1 FHA domain targeting the FHA binding motif that inhibits normal substrate binding between a substrate protein and the Peli1 protein may be usefully used in the development of new drugs for psoriasis-associated diseases. Moreover, by confirming an expression level of the Peli1 protein, it is anticipated to be usefully used in evaluating the severity of patients with psoriasis.
    Type: Application
    Filed: September 8, 2020
    Publication date: December 24, 2020
    Applicant: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Chang Woo LEE, Heoun Jeong GO, Su Hyeon KIM, Seo Yoon BAE
  • Publication number: 20190281797
    Abstract: Provided are a psoriasis-induced transgenic animal model overexpressing the Pellino homolog 1 (Peli1) gene according to doxycycline administration, and a use thereof. The transgenic animal model of the present disclosure exhibited similarity to phenotypes shown in patients with psoriasis, due to overexpression of the Pellino homolog 1 (Peli1) gene according to doxycycline administration. It is anticipated that the transgenic animal model may be usefully used in clinical studies, such as screening for a candidate drug for the treatment of psoriasis. Additionally, it is anticipated that a peptide derived from the Peli1 FHA domain targeting the FHA binding motif that inhibits normal substrate binding between a substrate protein and the Peli1 protein may be usefully used in the development of new drugs for psoriasis-associated diseases. Moreover, by confirming an expression level of the Peli1 protein, it is anticipated to be usefully used in evaluating the severity of patients with psoriasis.
    Type: Application
    Filed: June 30, 2017
    Publication date: September 19, 2019
    Applicants: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, THE ASAN FOUNDATION
    Inventors: Chang Woo LEE, Heoun Jeong GO, Su Hyeon KIM, Seo Yoon BAE